Nkarta, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Nkarta, Inc. has submitted its 2023 annual report (10-K), detailing its financial status and business operations for the fiscal year ending December 31, 2023.</b>

AI Summary

Nkarta, Inc. (NKTX) filed a Annual Report (10-K) with the SEC on March 21, 2024. Nkarta, Inc. filed its 2023 Form 10-K on March 21, 2024. The filing covers the fiscal year ending December 31, 2023. Nkarta, Inc. is a pharmaceutical preparations company (SIC 2834). The company's principal business address is in South San Francisco, California. The filing includes details on various financial instruments and agreements, such as stock options, lease agreements, and license agreements.

Why It Matters

For investors and stakeholders tracking Nkarta, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Nkarta's financial health, operational activities, and strategic positioning for the past fiscal year, which is crucial for investors to assess the company's performance and future prospects. The detailed information on financial instruments, equity plans, and various agreements offers insights into the company's capital structure, compensation strategies, and key business relationships, impacting its operational and financial risk profile.

Risk Assessment

Risk Level: medium — Nkarta, Inc. shows moderate risk based on this filing. The company is in the pharmaceutical preparations industry, which is subject to significant regulatory oversight, lengthy development cycles, and high R&D costs, as indicated by its SIC code and the nature of its business.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Nkarta's current financial position and potential challenges in drug development and commercialization.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-03-21 — Filing Date (Date of submission)
• 0000950170-24-034735 — Accession Number (Unique identifier for the filing)

Key Players & Entities

• Nkarta, Inc. (company) — Filer name
• 2024-03-21 (date) — Filing date
• 2023-12-31 (date) — Fiscal year end
• South San Francisco, CA (location) — Business address
• 2834 (industry_code) — Standard Industrial Classification
• 10-K (document_type) — Form type

FAQ

Risk Factors

• Regulatory Risks [high — regulatory]: The pharmaceutical industry is subject to extensive government regulation, which can impact product development, manufacturing, and marketing.
• Funding and Liquidity [high — financial]: The company's ability to fund its operations and development programs depends on its access to capital and its cash reserves.
• Clinical Trial Risks [high — operational]: The success of drug candidates relies heavily on the outcomes of clinical trials, which are inherently uncertain and can face delays or failures.
• Competition [medium — market]: The biotechnology and pharmaceutical markets are highly competitive, with many companies developing similar therapies.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
• 2024-03-21: Filing Date — Date Nkarta, Inc. submitted its 10-K to the SEC.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share NKTX Nasdaq Glo

Filing Documents

• nktx-20231231.htm (10-K) — 2665KB
• nktx-ex4_3.htm (EX-4.3) — 32KB
• nktx-ex10_6d.htm (EX-10.6(D)) — 37KB
• nktx-ex23_1.htm (EX-23.1) — 9KB
• nktx-ex31_1.htm (EX-31.1) — 15KB
• nktx-ex31_2.htm (EX-31.2) — 15KB
• nktx-ex32.htm (EX-32) — 14KB
• nktx-ex97.htm (EX-97) — 21KB
• img179161570_0.jpg (GRAPHIC) — 63KB
• img184572170_0.jpg (GRAPHIC) — 73KB
• img184572170_1.jpg (GRAPHIC) — 72KB
• img184572170_2.jpg (GRAPHIC) — 114KB
• img184572170_3.jpg (GRAPHIC) — 74KB
• img184572170_4.jpg (GRAPHIC) — 51KB
• img184572170_5.jpg (GRAPHIC) — 40KB
• img184572170_6.jpg (GRAPHIC) — 125KB
• img184572170_7.jpg (GRAPHIC) — 77KB
• img184572170_8.jpg (GRAPHIC) — 108KB
• img184572170_9.jpg (GRAPHIC) — 101KB
• 0000950170-24-034735.txt (&nbsp;) — 11962KB
• nktx-20231231.xsd (EX-101.SCH) — 1407KB
• nktx-20231231_htm.xml (XML) — 1472KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 38 Item 1B. Unresolved Staff Comments 99 Item 1C. Cybersecurity 99 Item 2.

Properties

Properties 100 Item 3.

Legal Proceedings

Legal Proceedings 100 Item 4. Mine Safety Disclosures 100 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 101 Item 6. [Reserved] 102 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 103 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 112 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 113 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 138 Item 9A.

Controls and Procedures

Controls and Procedures 138 Item 9B. Other Information 139 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 139 PART III Item 10. Directors, Executive Officers and Corporate Governance 140 Item 11.

Executive Compensation

Executive Compensation 140 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 140 Item 13. Certain Relationships and Related Transactions, and Director Independence 140 Item 14. Principal Accountant Fees and Services 140 PART IV Item 15. Exhibits and Financial Statement Schedules 141 Item 16 Form 10-K Summary 145

Signatures

Signatures 146 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K, and the information incorporated herein by reference, particularly in the sections captioned "Business" under Part I, Item 1, "Risk Factors" under Part I, Item 1A, and "Management's Discussion and Analysis of Financial Condition and Results of Operations" under Part II, Item 7, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In some cases, you can identify forward-looking statements by the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict," "project," "potential," "should," "will," or "would," or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In addition, these statements are based on our management's beliefs and assumptions and on information currently available to our management as of the date of this Annual Report on Form 10-K. While we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. You should read the sections titled "Risk Factor Summary" below and "Risk Factors" set forth in Part I, Item 1A of this Annual Repor

B usiness

Item 1. B usiness. Overview We are a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer ("NK") cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. Our company was founded on the belief that engineered NK cell therapies can transform the lives of patients by offering therapies that are clinically meaningful, broadly accessible and unencumbered by the safety concerns often associated with other cell therapy approaches. We are currently developing NKX019, a chimeric antigen receptor-natural killer ("CAR NK") product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. NKX019 and NKX101 incorporate proprietary technologies that enable us to generate an abundant supply of NK cells, increase NK cell recognition of target antigens, enhance NK cell fitness, and freeze, store and thaw our engineered NK cells for off-the-shelf administration. Our product candidates are allogeneic, which means they are produced using cells from a different person than the patient(s) being treated, and they are produced in quantity, then frozen and therefore available for treating patients without delay, unlike autologous cell therapies, which are derived from a patient's own cells and must be manufactured as needed for each patient. We believe that engineered NK cells have the potential to be effective and accessible therapies for autoimmune diseases and cancer, be well tolerated, and avoid some of the toxicities observed with other cell therapies. NKX019 is currently being studied in an ongoing Phase 1 clinical trial for certain B-cell malignancies, and preparations for a planned Phase 1 clinical trial of NKX019 for lupus nephritis ("LN") are underway. NKX101 has been studied in a Ph

View Full Filing

View this 10-K filing on SEC EDGAR